APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Sustained-release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026

27 December 2025194 pages

Choose your research edition.

Industry ResearchMirabegron Sustained-release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Mirabegron Sustained-release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mirabegron Sustained-release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mirabegron Sustained-release Tablets market include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mirabegron Sustained-release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mirabegron Sustained-release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mirabegron Sustained-release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mirabegron Sustained-release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Mirabegron Sustained-release Tablets Segment by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet

50mg per Tablet

Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Mirabegron Sustained-release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mirabegron Sustained-release Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mirabegron Sustained-release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mirabegron Sustained-release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Mirabegron Sustained-release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mirabegron Sustained-release Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mirabegron Sustained-release Tablets industry.

Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mirabegron Sustained-release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mirabegron Sustained-release Tablets Industry Trends Table 2. Mirabegron Sustained-release Tablets Industry Drivers Table 3. Mirabegron Sustained-release Tablets Industry Opportunities and Challenges Table 4. Mirabegron Sustained-release Tablets Industry Restraints Table 5. Global Mirabegron Sustained-release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mirabegron Sustained-release Tablets Revenue Share by Company (2021-2026) Table 7. Global Mirabegron Sustained-release Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Mirabegron Sustained-release Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Mirabegron Sustained-release Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Mirabegron Sustained-release Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mirabegron Sustained-release Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Mirabegron Sustained-release Tablets Company, Product Type & Application Table 13. Global Mirabegron Sustained-release Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mirabegron Sustained-release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 25mg per Tablet Table 18. Significant Companies of 50mg per Tablet Table 19. Global Mirabegron Sustained-release Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Mirabegron Sustained-release Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Mirabegron Sustained-release Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Mirabegron Sustained-release Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Mirabegron Sustained-release Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Mirabegron Sustained-release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Mirabegron Sustained-release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Mirabegron Sustained-release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Mirabegron Sustained-release Tablets Sales Value Share by Type (2021-2026) Table 28. Global Mirabegron Sustained-release Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Mirabegron Sustained-release Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Mirabegron Sustained-release Tablets Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Mirabegron Sustained-release Tablets Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Mirabegron Sustained-release Tablets Sales Volume Share by Application (2021-2026) Table 36. Global Mirabegron Sustained-release Tablets Sales Volume Share by Application (2027-2032) Table 37. Global Mirabegron Sustained-release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Mirabegron Sustained-release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Mirabegron Sustained-release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Mirabegron Sustained-release Tablets Sales Value Share by Application (2021-2026) Table 41. Global Mirabegron Sustained-release Tablets Sales Value Share by Application (2027-2032) Table 42. Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (K Units) Table 44. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2026) Table 45. Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032) & (K Units) Table 46. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2027-2032) Table 47. Global Mirabegron Sustained-release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Mirabegron Sustained-release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Mirabegron Sustained-release Tablets Sales Value Share by Region (2021-2026) Table 50. Global Mirabegron Sustained-release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Mirabegron Sustained-release Tablets Sales Value Share by Region (2027-2032) Table 52. Global Mirabegron Sustained-release Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Mirabegron Sustained-release Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Mirabegron Sustained-release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 57. Global Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 58. Global Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 59. Global Mirabegron Sustained-release Tablets Sales Market Share by Country (2027-2032) Table 60. Global Mirabegron Sustained-release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Mirabegron Sustained-release Tablets Sales Value Market Share by Country (2021-2026) Table 62. Global Mirabegron Sustained-release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Mirabegron Sustained-release Tablets Sales Value Market Share by Country (2027-2032) Table 64. Alkem Laboratories Company Information Table 65. Alkem Laboratories Business Overview Table 66. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio Table 68. Alkem Laboratories Recent Development Table 69. Astellas Pharma Company Information Table 70. Astellas Pharma Business Overview Table 71. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio Table 73. Astellas Pharma Recent Development Table 74. Lupin Pharmaceuticals Company Information Table 75. Lupin Pharmaceuticals Business Overview Table 76. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 78. Lupin Pharmaceuticals Recent Development Table 79. Zydus Lifesciences Company Information Table 80. Zydus Lifesciences Business Overview Table 81. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio Table 83. Zydus Lifesciences Recent Development Table 84. China Resources Pharmaceutical Company Information Table 85. China Resources Pharmaceutical Business Overview Table 86. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 88. China Resources Pharmaceutical Recent Development Table 89. Jiangsu Huayang Pharmaceutical Company Information Table 90. Jiangsu Huayang Pharmaceutical Business Overview Table 91. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 93. Jiangsu Huayang Pharmaceutical Recent Development Table 94. Jiangxi Shanxiang Pharmaceutical Company Information Table 95. Jiangxi Shanxiang Pharmaceutical Business Overview Table 96. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 98. Jiangxi Shanxiang Pharmaceutical Recent Development Table 99. Qilu Pharmaceutical Company Information Table 100. Qilu Pharmaceutical Business Overview Table 101. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 103. Qilu Pharmaceutical Recent Development Table 104. Shenzhen Main Luck Pharmaceuticals Company Information Table 105. Shenzhen Main Luck Pharmaceuticals Business Overview Table 106. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 108. Shenzhen Main Luck Pharmaceuticals Recent Development Table 109. CSPC Pharmaceutical Company Information Table 110. CSPC Pharmaceutical Business Overview Table 111. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 113. CSPC Pharmaceutical Recent Development Table 114. Sichuan Gowell Pharmaceutical Company Information Table 115. Sichuan Gowell Pharmaceutical Business Overview Table 116. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 118. Sichuan Gowell Pharmaceutical Recent Development Table 119. Zhejiang Huayi Pharmaceutical Company Information Table 120. Zhejiang Huayi Pharmaceutical Business Overview Table 121. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 123. Zhejiang Huayi Pharmaceutical Recent Development Table 124. Chia Tai Tianqing Pharmaceutical Company Information Table 125. Chia Tai Tianqing Pharmaceutical Business Overview Table 126. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 128. Chia Tai Tianqing Pharmaceutical Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Mirabegron Sustained-release Tablets Distributors List Table 132. Mirabegron Sustained-release Tablets Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Mirabegron Sustained-release Tablets Product Image Figure 2. Global Mirabegron Sustained-release Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mirabegron Sustained-release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Mirabegron Sustained-release Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Mirabegron Sustained-release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 25mg per Tablet Image Figure 10. 50mg per Tablet Image Figure 11. Global Mirabegron Sustained-release Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Mirabegron Sustained-release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Mirabegron Sustained-release Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Mirabegron Sustained-release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Mirabegron Sustained-release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Mirabegron Sustained-release Tablets Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Mirabegron Sustained-release Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Mirabegron Sustained-release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Mirabegron Sustained-release Tablets Sales Volume Share by Application (2021-2032) Figure 23. Global Mirabegron Sustained-release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Mirabegron Sustained-release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Mirabegron Sustained-release Tablets Sales Value Share by Application (2021-2032) Figure 26. Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Mirabegron Sustained-release Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Mirabegron Sustained-release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Mirabegron Sustained-release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 31. North America Mirabegron Sustained-release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Mirabegron Sustained-release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Mirabegron Sustained-release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 37. South America Mirabegron Sustained-release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Mirabegron Sustained-release Tablets Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Mirabegron Sustained-release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Mirabegron Sustained-release Tablets Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Mirabegron Sustained-release Tablets Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg per Tablet
  • 50mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Mirabegron Sustained-release Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Mirabegron Sustained-release Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mirabegron Sustained-release Tablets Market Dynamics
  1. 2.1 Mirabegron Sustained-release Tablets Industry Trends
  2. 2.2 Mirabegron Sustained-release Tablets Industry Drivers
  3. 2.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
  4. 2.4 Mirabegron Sustained-release Tablets Industry Restraints
3 Mirabegron Sustained-release Tablets Market by Company
  1. 3.1 Global Mirabegron Sustained-release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Mirabegron Sustained-release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Mirabegron Sustained-release Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Mirabegron Sustained-release Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Mirabegron Sustained-release Tablets Company Ranking (2024-2026)
  6. 3.6 Global Mirabegron Sustained-release Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Mirabegron Sustained-release Tablets Company Product Type and Application
  8. 3.8 Global Mirabegron Sustained-release Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mirabegron Sustained-release Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mirabegron Sustained-release Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mirabegron Sustained-release Tablets Market by Type
  1. 4.1 Mirabegron Sustained-release Tablets Type Introduction
  2. 4.1.1 25mg per Tablet
  3. 4.1.2 50mg per Tablet
  4. 4.2 Global Mirabegron Sustained-release Tablets Sales Volume by Type
  5. 4.2.1 Global Mirabegron Sustained-release Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mirabegron Sustained-release Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Mirabegron Sustained-release Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Mirabegron Sustained-release Tablets Sales Value by Type
  9. 4.3.1 Global Mirabegron Sustained-release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Mirabegron Sustained-release Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Mirabegron Sustained-release Tablets Sales Value Share by Type (2021-2032)
5 Mirabegron Sustained-release Tablets Market by Application
  1. 5.1 Mirabegron Sustained-release Tablets Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Mirabegron Sustained-release Tablets Sales Volume by Application
  6. 5.2.1 Global Mirabegron Sustained-release Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mirabegron Sustained-release Tablets Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Mirabegron Sustained-release Tablets Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Mirabegron Sustained-release Tablets Sales Value by Application
  10. 5.3.1 Global Mirabegron Sustained-release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Mirabegron Sustained-release Tablets Sales Value by Application (2021-2032)
  12. 5.3.3 Global Mirabegron Sustained-release Tablets Sales Value Share by Application (2021-2032)
6 Mirabegron Sustained-release Tablets Regional Sales and Value Analysis
  1. 6.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mirabegron Sustained-release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032)
  5. 6.3 Global Mirabegron Sustained-release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mirabegron Sustained-release Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mirabegron Sustained-release Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mirabegron Sustained-release Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Mirabegron Sustained-release Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Mirabegron Sustained-release Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Mirabegron Sustained-release Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mirabegron Sustained-release Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Mirabegron Sustained-release Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mirabegron Sustained-release Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mirabegron Sustained-release Tablets Sales Value Share by Country, 2025 VS 2032
7 Mirabegron Sustained-release Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mirabegron Sustained-release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Mirabegron Sustained-release Tablets Sales by Country (2027-2032)
  6. 7.4 Global Mirabegron Sustained-release Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mirabegron Sustained-release Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mirabegron Sustained-release Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mirabegron Sustained-release Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mirabegron Sustained-release Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mirabegron Sustained-release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alkem Laboratories
  2. 8.1.1 Alkem Laboratories Company Information
  3. 8.1.2 Alkem Laboratories Business Overview
  4. 8.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
  6. 8.1.5 Alkem Laboratories Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Lupin Pharmaceuticals
  14. 8.3.1 Lupin Pharmaceuticals Company Information
  15. 8.3.2 Lupin Pharmaceuticals Business Overview
  16. 8.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  18. 8.3.5 Lupin Pharmaceuticals Recent Developments
  19. 8.4 Zydus Lifesciences
  20. 8.4.1 Zydus Lifesciences Company Information
  21. 8.4.2 Zydus Lifesciences Business Overview
  22. 8.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
  24. 8.4.5 Zydus Lifesciences Recent Developments
  25. 8.5 China Resources Pharmaceutical
  26. 8.5.1 China Resources Pharmaceutical Company Information
  27. 8.5.2 China Resources Pharmaceutical Business Overview
  28. 8.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  30. 8.5.5 China Resources Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Huayang Pharmaceutical
  32. 8.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 8.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 8.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  36. 8.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 8.7 Jiangxi Shanxiang Pharmaceutical
  38. 8.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 8.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 8.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  42. 8.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Shenzhen Main Luck Pharmaceuticals
  50. 8.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 8.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 8.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  54. 8.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 8.10 CSPC Pharmaceutical
  56. 8.10.1 CSPC Pharmaceutical Company Information
  57. 8.10.2 CSPC Pharmaceutical Business Overview
  58. 8.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  60. 8.10.5 CSPC Pharmaceutical Recent Developments
  61. 8.11 Sichuan Gowell Pharmaceutical
  62. 8.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 8.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 8.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  66. 8.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 8.12 Zhejiang Huayi Pharmaceutical
  68. 8.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 8.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 8.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  72. 8.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 8.13 Chia Tai Tianqing Pharmaceutical
  74. 8.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 8.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 8.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  78. 8.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mirabegron Sustained-release Tablets Value Chain Analysis
  2. 9.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mirabegron Sustained-release Tablets Sales Mode & Process
  6. 9.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mirabegron Sustained-release Tablets Distributors
  9. 9.2.3 Mirabegron Sustained-release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst